source
- Sandoz announces $300 million biosimilar factory in Slovenia and plans to expand pipeline sevenfoldSandoz, the generic and biosimilar division of Novartis, said it will invest $300 million to build a new biosimilar manufacturing facility in Slovenia. The company also announced that its newly cr…
- Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapyBristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing…